Oren Gilad

CIK: 0001929300

Transaction Breakdown

Open Market Buys (P)9 (81.8%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (18.2%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

APRE

Aprea Therapeutics, Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (11 total)

APRE
Aprea Therapeutics, Inc.
Mar 12, 2026
Award(A)
Direct
20.2K shares-
APRE
Aprea Therapeutics, Inc.
Jan 30, 2026
Purchase(P)
Direct
28.1K shares at avg. $0.89$25K
APRE
Aprea Therapeutics, Inc.
Dec 10, 2025
Purchase(P)
Common Warrants
Direct
21.5K shares-
APRE
Aprea Therapeutics, Inc.
Dec 10, 2025
Purchase(P)
Pre-Funded Warrant
Direct
21.5K shares at avg. $1.17-
APRE
Aprea Therapeutics, Inc.
Apr 3, 2025
Purchase(P)
Direct
3K shares at avg. $1.87$6K
APRE
Aprea Therapeutics, Inc.
Apr 3, 2025
Purchase(P)
Direct
2.5K shares at avg. $1.80$4K
APRE
Aprea Therapeutics, Inc.
Mar 27, 2025
Award(A)
Direct
6.7K shares-
APRE
Aprea Therapeutics, Inc.
Oct 23, 2024
Purchase(P)
Direct
500 shares at avg. $3.92$2K
APRE
Aprea Therapeutics, Inc.
Oct 15, 2024
Purchase(P)
Direct
250 shares at avg. $2.90$725
APRE
Aprea Therapeutics, Inc.
Oct 14, 2024
Purchase(P)
Direct
1K shares at avg. $2.59$3K
APRE
Aprea Therapeutics, Inc.
Oct 10, 2024
Purchase(P)
Direct
150 shares at avg. $2.54$381

		Type	Shares	Price		Ownership
Mar 12, 2026	APRE Aprea Therapeutics, Inc.	Award(A)	20,175	-	$0	Direct
Jan 30, 2026	APRE Aprea Therapeutics, Inc.	Purchase(P)	28,100	$0.89	$25,009	Direct
Dec 10, 2025	APRE Aprea Therapeutics, Inc.	Purchase(P) Common Warrants	21,459	-	-	Direct
Dec 10, 2025	APRE Aprea Therapeutics, Inc.	Purchase(P) Pre-Funded Warrant	21,459	$1.17	-	Direct
Apr 3, 2025	APRE Aprea Therapeutics, Inc.	Purchase(P)	3,003	$1.87	$5,616	Direct
Apr 3, 2025	APRE Aprea Therapeutics, Inc.	Purchase(P)	2,497	$1.80	$4,495	Direct
Mar 27, 2025	APRE Aprea Therapeutics, Inc.	Award(A)	6,725	-	-	Direct
Oct 23, 2024	APRE Aprea Therapeutics, Inc.	Purchase(P)	500	$3.92	$1,958	Direct
Oct 15, 2024	APRE Aprea Therapeutics, Inc.	Purchase(P)	250	$2.90	$725	Direct
Oct 14, 2024	APRE Aprea Therapeutics, Inc.	Purchase(P)	1,000	$2.59	$2,590	Direct
Oct 10, 2024	APRE Aprea Therapeutics, Inc.	Purchase(P)	150	$2.54	$381	Direct

1-11 of 11 transactions

About Gilad Oren

Gilad Oren (SEC CIK 0001929300) files insider reports with the SEC as President/CEO of Aprea Therapeutics, Inc. (APRE).

Signal8 holds 8 ownership filings by Gilad Oren, all Form 4s, filed between Oct 15, 2024 and Mar 16, 2026. Those filings report 11 transactions, from Oct 10, 2024 to Mar 12, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Gilad Oren's filings is in DOYLESTOWN, PA.

Recent filings by Gilad Oren

Mar 12, 2026: Grant or award of APRE shares (Form 4, code A).
Jan 30, 2026: Open-market purchase of APRE shares (Form 4, code P).
Dec 10, 2025: Open-market purchases of APRE derivative securities (2 lines, Form 4, code P).
Apr 3, 2025: Open-market purchases of APRE shares (2 lines, Form 4, code P).
Mar 27, 2025: Grant or award of APRE shares (Form 4, code A).

Other insiders filing for Aprea Therapeutics, Inc. (APRE)

Grissinger Michael, Director
Gruia Gabriela, Director
Peters Richard, Director
HENNEMAN JOHN B III, Director
BIZZARI JEAN-PIERRE, Director
Duey Marc, Director

How to read Form 4 transaction codes